Health News Releases

  • Today September 26
June 21, 16:35
Waters and BioInfra Establish the ASEAN Academy for Bioanalysis to Promote Analytical Skills Development
Waters Corporation (NYSE:WAT) announced a collaboration with BioInfra, a pioneering contract research organization (CRO) company for the pharmaceutical and clinical fields, to jointly establish the AS
June 21, 16:16
Companies in the Global Omics Based Clinical Trials Market Expedite Product Innovations to Stay at Forefront; Expected Sales to Reach USD 61.7 Bn By 2032: Fact.MR’s Study
The Omics Based Clinical Trials Market revenues were estimated at USD 26.2 Bn in 2021 and is anticipated to grow at a CAGR of 8.1% from 2022 to 2032, according to a recently published Fact.MR report.
June 21, 15:45
AOP Health Presents Final Results From Its CONTINUATION-PV Study - up to 7.5 Years Treatment With BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera Patients - at EHA 2022 Annual Meeting
AOP Health announced the final results on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from its CONTINUATION-PV study in an oral presentation at the prestigious EHA (European Hemat
June 20, 16:30
Solasia Pharma: DARVIAS® Injection 135mg (Generic Name: DARINAPARSIN /Development Code: SP-02) Approved in Japan
Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP
June 20, 14:30
Increasing Prevalence of Diabetic Ketoacidosis Is Expected to Drive Growth of Blood Ketone Meter Market: Fact.MR’s Study
The Blood Ketone Meter market revenues were estimated at US$ 275 Mn in 2021 and are anticipated to grow at a CAGR of 8.1% from 2022-2032 according to a recently published Fact.MR report. By the en
June 17, 17:40
IFPMA: Pharmaceutical Industry Expresses Deep Disappointment With Decision on Waiving Intellectual Property Rights Adopted at the World Trade Organization Ministerial Conference
Today’s decision at the World Trade Organization (WTO) Ministerial Conference (MC12) to endorse a TRIPS waiver for COVID-19 vaccines sends the wrong message to those carrying out research and developm
June 16, 15:50
Alvotech, a Global Pureplay Biosimilars Company, to Debut on Nasdaq Under the Ticker ALVO on June 16
Alvotech, a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide today announced that its ordinary shares and warrants will begin tra
June 16, 11:55
Saint-Gobain Bioprocess Solutions Business Announces C-Flex® Production Capability in Suwa, Japan
Saint-Gobain Life Sciences today announced the addition of their Suwa, Japan manufacturing facility for the production of C-Flex® TPE tubing for use in bioprocessing. The capacity addition in Suwa is
June 16, 10:55
GC Aesthetics® Announces Growth and Expansion in Brazil
GC Aesthetics®, Inc. (GCA), a privately-held medical technology company providing Women Healthcare Aesthetic and Reconstructive Solutions, has announced today, its growth and expansion plans for the B
June 15, 15:40
ValGenesis Acquires 4Tune Engineering, Extends Product Portfolio with Best-in-Class Risk Management and Continuous Process Verification Software Platforms
ValGenesis, Inc., the market leader in enterprise Validation Lifecycle Management Systems (VLMS), has acquired Portugal-based 4Tune Engineering (4TE), a leader in manufacturing sciences and technologi
June 15, 14:50
KBI Biopharma SA and Selexis SA Expand in Europe by Opening an Integrated Biologics Manufacturing Facility in Geneva, Switzerland
KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, announced today that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now op
June 15, 09:50
Boehringer Ingelheim signs Option to Acquire Trutino Biosciences
Boehringer Ingelheim today announced the signing of an option to acquire Trutino Biosciences Inc. (the “Transaction”), a San Diego-based biotech company. Trutino Biosciences is a pre-clinical stage
June 14, 10:40
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it has purchased the remaining shares of Guardant Health AMEA, Inc., held by SoftBank and its affiliates, givin
June 13, 11:25
Galderma Announces Positive Results in Two Phase III Studies for a Novel Liquid Formulation botulinumtoxinA (RelabotulinumtoxinA) for the Treatment of Glabellar Lines (frown) and Lateral Canthal Lines (crow’s Feet)
Galderma announced today at the Vegas Cosmetic Surgery & Aesthetic Dermatology meeting, topline results from two phase III clinical studies (NCT04249583, NCT04249687) demonstrating that Relabotulinumt
June 10, 12:00
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial
Takeda (TSE:4502/NYSE:TAK) today announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases, with no important safety risks id
June 10, 10:30
Ferring Announces New Collaboration for Development of Olamkicept
Ferring Pharmaceuticals today announced it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions.
June 08, 16:40
Galderma to Present New Findings From Innovative Product Portfolio at the 2022 VCS Annual Symposium
Galderma, the leading company solely dedicated to advancing the future of dermatology, announced it will present four scientific presentations at the 2022 Vegas Cosmetic Surgery (VCS) & Aesthetic Derm
June 07, 16:20
Parse Biosciences Announces Partnership with Molecular Diagnostics Korea
Parse Biosciences, a leading provider of scalable single-cell sequencing solutions, today announced a partnership with Molecular Diagnostics Korea (MDxK) that will expand its presence in Asia by provi
June 07, 11:30
Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways
Merck, a leading science and technology company, today provided an update on the progress of the company’s innovative oncology development pipeline focused on DNA damage biology. With clinical program
June 07, 10:18
High Solvent Properties of N-Methyl-2-Pyrrolidone Dominate The Aprotic Solvents Industry: Report Fact.MR
As per in-depth industry analysis by Fact.MR, a market research and competitive intelligence provider, the global aprotic solvents market is anticipated to rise at a CAGR of 4.2% from 2022 to 2032.
June 03, 14:20
On One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report
Organon (NYSE: OGN), a global women’s healthcare company, today announced the publication of its inaugural Environmental, Social, and Governance (ESG) Report for 2021. The ESG Report introduces Organo
June 03, 11:30
BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES
Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights t
June 02, 11:40
Galderma to Present Extensive New Clinical Data Across Its Portfolio of Neuromodulators, Fillers and Biostimulators at the IMCAS World Congress 2022
Galderma will present a range of new clinical data and analyses across its portfolio during nine poster sessions and two symposia at the upcoming International Master Course on Aging Science (IMCAS) W
June 02, 11:15
Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present data at two upcoming scientific congresses this spring: the 58th Annual Meeting of the America
June 02, 10:20
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda (TSE:4502/NYSE:TAK) announced to transfer the marketing authorization in Jap
25 per page50 per page75 per page100 per page